Agile Therapeutics (NASDAQ:AGRX) was downgraded by equities research analysts at Janney Montgomery Scott from a “buy” rating to a “neutral” rating in a report issued on Friday, December 22nd, Marketbeat.com reports.
A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 price target on shares of Agile Therapeutics in a report on Monday, November 20th. Royal Bank of Canada lifted their price target on shares of Agile Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, September 14th. HC Wainwright set a $10.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Finally, ValuEngine downgraded shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $9.20.
Agile Therapeutics (NASDAQ AGRX) opened at $3.28 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.10 and a current ratio of 4.10. Agile Therapeutics has a one year low of $1.93 and a one year high of $5.60. The firm has a market cap of $110.08, a price-to-earnings ratio of -3.57 and a beta of 2.01.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. research analysts expect that Agile Therapeutics will post -0.97 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Pura Vida Investments LLC increased its holdings in shares of Agile Therapeutics by 65.9% in the 3rd quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after buying an additional 115,000 shares during the last quarter. Neuberger Berman Group LLC bought a new stake in shares of Agile Therapeutics in the 3rd quarter worth about $613,000. Alyeska Investment Group L.P. bought a new position in Agile Therapeutics during the 3rd quarter valued at about $3,747,000. Caxton Corp grew its holdings in Agile Therapeutics by 12.1% during the 3rd quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock valued at $8,117,000 after purchasing an additional 196,445 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new position in Agile Therapeutics during the 3rd quarter valued at about $161,000. Hedge funds and other institutional investors own 72.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Agile Therapeutics (AGRX) Stock Rating Lowered by Janney Montgomery Scott” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/14/janney-montgomery-scott-downgrades-agile-therapeutics-agrx-to-neutral-2-updated-updated-updated.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.